CSL112 phase 2b trial result could provide a big upside surprise, the phase 2a data was promising. A new plasma based therapy to decrease the risk of heart attack would be massive. CSL have a strong track record in bringing novel therapies to market, well managed and worth hanging on to.
COULD CSL BE WORTH MORE THAN $150 A SHARE?
http://rogermontgomery.com/could-csl-be-worth-more-than-150-a-share/
http://uknowledge.uky.edu/cgi/viewcontent.cgi?article=1008&context=heart_facpub
http://www.ahjonline.com/article/S0002-8703(16)30108-9/abstract
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$247.27 |
Change
4.510(1.86%) |
Mkt cap ! $119.8B | |||
| Open | High | Low | Value | Volume |
| $243.56 | $247.96 | $243.53 | $65.49M | 265.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1 | $247.27 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $247.29 | 54 | 5 |
View Market Depth
| Last trade - 13.10pm 07/07/2025 (20 minute delay) ? |
| CSL (ASX) Chart |